Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): The Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study

Diabetes, Obesity and Metabolism

Volumn 8, Issue 1, 2006, Pages 49-57

  Rosenstock, Julio ^a,e   Goldstein, B J ^b   Vinik, A I ^c   O'Neill, M Colleen ^d   Porter, L E ^d   Heise, M A ^d   Kravitz, B ^d   Dirani, R G ^d   Freed, M I ^d   Aronson, Ronnie ^e   Bailey, Gordon ^e   Boctor, Makram ^e   Hardin, Philip ^e   Joyce, Carol ^e   Nadeau, Andre ^e   Rodger, Wilson ^e   Tildesley, Hugh ^e   Woo, Vincent ^e   Yale, Jean Francois ^e   Alwine, Lawrence ^e   Braun, Alan ^e   Burgess, Geoffrey ^e   Cathcart, Harold Kennedy ^e   Chao, George ^e   Dobs, Andrian ^e   Douglas, Bruce Clayton ^e   Edgar, Paul ^e   Eil, Charles ^e   Evans, J Gary ^e   Fallon, Joseph ^e   Gilbert Jr , John Gilbert ^e   Goldstein, Barry ^e   Groch, George ^e   Haag, Burritt ^e   Harris, Michael ^e   Heatley, Scott ^e   Hollander, Priscilla ^e   Horst, Eric ^e   Hurley, Sean ^e   James, Andrian ^e   Katzeff, Harvey ^e   Kaye, William ^e   Keiller, Danny ^e   Knecht, Thomas ^e   Lorber, Daniel ^e   Lucas, Kathryn Jean ^e   Marks, Jennifer ^e   Masharani, Umesh ^e   McClanahan, Mark ^e   McKenney, James ^e   Michlin, Bernard ^e   Miller, David ^e   Neutel, Joel ^e   Ovalle, Fernando ^e   Pi Sunyer, Xavier ^e   Mezitis, Nicholas ^e   Radbill, Mark ^e   Rosenblatt, Sid ^e   Scott, Graham ^e   Seibel, John ^e   Smith, William ^e   Synder, James ^e   Steckel, Alan ^e   Steinbrenner, Roger ^e   Stotler, Charles ^e   Sussman, Allen ^e   Troupin, Barbara ^e   Vadakekalam, Jacob ^e   Vinik, Aaron ^e   Winkle, Peter ^e   Yanez, Jose ^e   Zieve, Franklin ^e   more..

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^d GLAXOSMITHKLINE   (United States)

^e NONE

Author keywords

Early combination treatment; Elderly subjects; Glycaemic control; Rosiglitazone; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; FATTY ACID; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD GLUCOSE MONITORING; BODY WEIGHT DISORDER; CANADA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ELDERLY CARE; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH CARE UTILIZATION; HEMOGLOBIN DETERMINATION; HUMAN; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPOCHOLESTEROLEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNITED STATES;

EID: 33645988220     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2005.00541.x     Document Type: Article

References (21)

1. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.
2. UK Prospective Diabetes Study (UKPDS) Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease. Diabetes 1995; 44: 1249-1258.
3. Stenman S, Melander A, Groop PH, Groop LC. What is the benefit of increasing the sulfonylurea dose? Ann Intern Med 1993; 118: 169-172.
4. Gerich JE. Redefining the clinical management of type 2 diabetes: matching therapy to pathophysiology. Eur J Clin Invest 2002; 32 (Suppl. 3): 46-53.
5. Rosenstock J. Management of type 2 diabetes mellitus in the elderly: special considerations. Drugs Aging 2001; 18: 31-44.
6. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003; 26 (Suppl. 1): S5-S20.
7. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
8. Bradley C. Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes. Diabet Med 1990; 7: 445-451.
9. Grootenhuis PA, Snoek FJ, Heine RJ, Bouter LM. Development of a type-2 diabetes symptom checklist: A measure of symptom severity. Diabet Med 1994; 11: 253-261.
10. Bradley C. Diabetes Treatment Satisfaction Questionnaire (DTSQ). In: Bradley C, ed. Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Management. Langhorne: Harwood Academic Publishers, 1994.
11. Ware J. SF-36 Health Survey: Manual & Interpretation Guide. Boston: Medical Outcomes Trust, 2003.
12. Garber AJ. Using dose-response characteristics of therapeutic agents for treatment decisions in type 2 diabetes. Diabetes Obes Metab 2000; 2: 139-147.
13. Saito I, Folsom AR, Brancati FL et al. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med 2000; 133: 81-91.
14. Vinik A, Yu D, Strow LJ. Long-term effect of rosiglitazone on pancreatic β-cell function and insulin resistance in older type-2 diabetes mellitus (T2DM) patients treated with sulfonylurea. Diabetes 2004; 53 (Suppl. 2): A162-P680.
15. McGarry JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999; 42: 128-138.
16. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46: 3-10.
17. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2002; 25 (Suppl. 1): S33-S49.
18. Miyazaki Y, Mahankali A, Matsuda M et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 2784-2791.
19. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-288.
20. Carey DG, Cowin GJ, Galloway GJ et al. Sensitivity effect of rosiglitazone on insulin and body composition in type 2 diabetic patients. Obes Res 2002; 10: 1008-1015.
21. Herman WH, Dirani RG, Horblyuk R et al. Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: Findings from the Rosiglitazone Early vs SULfonylurea Titration (RESULT) study. Am J Manag Care 2005; 11: 273-278.